Home Cart Sign in  
Chemical Structure| 1936529-65-5 Chemical Structure| 1936529-65-5

Structure of YKL-05-099
CAS No.: 1936529-65-5

Chemical Structure| 1936529-65-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

YKL-05-099 is a selective SIK inhibitor with IC50 values of 10 nM, 40 nM and 30 nM for SIK1, SIK2 and SIK3, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of YKL-05-099

CAS No. :1936529-65-5
Formula : C32H34ClN7O3
M.W : 600.11
SMILES Code : O=C1N(C2=NC=C(OC)C=C2)C3=NC(NC4=CC=C(C5CCN(C)CC5)C=C4OC)=NC=C3CN1C6=C(C)C=CC=C6Cl
MDL No. :MFCD31382123
InChI Key :VQINULODWGEVBB-UHFFFAOYSA-N
Pubchem ID :121596782

Safety of YKL-05-099

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow macrophages 312 nM 3 days YKL-05–099 inhibits osteoclast differentiation PMC8238509
Ocy454 cells 0.5 μM 4 hours Suppressed SOST expression and upregulated RANKL expression PMC5075806
Bone marrow macrophages 15 μM 60 minutes YKL-05–099 blocks M-CSF-induced M-CSFR autophosphorylation and ERK1/2 phosphorylation PMC8238509
LP9 cells 1 µM 72 hours Evaluate the cytotoxic effect of YKL-05-099 on LP9 cells, results showed lower cytotoxicity when combined with prexasertib in LP9 cells PMC9021191
BER-DSRCT cells 1 µM 72 hours Evaluate the cytotoxic effect of YKL-05-099 on DSRCT cells, results showed significant increase in cytotoxicity when combined with prexasertib in BER cells PMC9021191
JN-DSRCT-1 cells 1 µM 72 hours Evaluate the cytotoxic effect of YKL-05-099 on DSRCT cells, results showed significant increase in cytotoxicity when combined with prexasertib in JN cells PMC9021191

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Ovariectomy model Intraperitoneal injection 18 mg/kg 5 times per week for 4 weeks YKL-05–099 increases bone formation without increasing bone resorption PMC8238509
C57BL/6J mice Chow diet-fed Intraperitoneal injection 10 or 20 mg/kg Once daily for 10 days Assess YKL-05-099's promotion of adipose tissue browning, showing upregulated Ucp1, Pgc1a, and Dio2 gene expression in subcutaneous fat and appearance of UCP1-positive adipocytes PMC10319839
Mice Wild-type mice Intraperitoneal injection 30 mg/kg Single injection, duration 3 hours To investigate the effect of YKL-05-099 on the expression of Cyp27b1 and Cyp24a1 genes. Results showed that YKL-05-099 could induce Cyp27b1 expression and suppress Cyp24a1 expression, similar to the actions of PTH. PMC9637672

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.33mL

1.67mL

0.83mL

16.66mL

3.33mL

1.67mL

References

 

Historical Records

Categories